RecruitingHepatocellular Carcinoma
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
Eligible age
18+ yrs
Accepts
All genders
Locations
24 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Sponsor: Genentech, Inc.
Where it's recruiting
Arizona
Tucson
California
La Jolla · Los Angeles · Newport Beach · Orange …
Colorado
Denver
Connecticut
Hartford
District of Columbia
Washington D.C.
Florida
Orlando
Illinois
Chicago
Kentucky
Lexington
Louisiana
Baton Rouge
Massachusetts
Boston
Michigan
Ann Arbor · Detroit
Missouri
Kansas City
Source: ClinicalTrials.gov · NCT06096779 · last updated 2026-06-01